Asthma, COPD, Respiratory, and Allergic Health Effects in an Adult Population Living near an Italian Refinery: A Cross-Sectional Study.
asthma
cross-sectional study
respiratory disease
Journal
Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525
Informations de publication
Date de publication:
04 Apr 2023
04 Apr 2023
Historique:
received:
01
02
2023
revised:
31
03
2023
accepted:
02
04
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
Asthma and chronic obstructive pulmonary disease (COPD) are leading causes of morbidity and mortality worldwide. Globally, 545 million people suffer from chronic respiratory diseases with a wide geographical variability. Risk factors for asthma are both genetic and related to several environmental factors (internal and external pollutants); these also have an important role in the occurrence of COPD. The aim of this study was to describe the prevalence of asthma, COPD, and asthma/COPD overlap (ACO) in an adult population living in two municipalities located in the Po Valley. A standardized questionnaire on respiratory symptoms and sociodemographic characteristics was self-administered to a random sample of the adult population aged 20-64 years, living near a refinery in Northern Italy during the period between 2016 and 2019. Logistic and multinomial regression were implemented to explore factors associated with asthma, COPD, and ACO. In total, 1108 subjects filled out the questionnaire, the mean age was 48.02 ± 12.34 years (range 21-68), and 53% of the respondents/participants were female. Half of the responders were non-smokers, but the frequency of current and former smokers was significantly greater in men than in women ( Respiratory diseases such as asthma and COPD are common in the general population, with differences among countries worldwide. Our findings show, on the basis of the main confirmed risk factor, namely smoking, that it is useful to plan target programs and actions in order to reduce smoking, thus improving the quality of life in public health.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Asthma and chronic obstructive pulmonary disease (COPD) are leading causes of morbidity and mortality worldwide. Globally, 545 million people suffer from chronic respiratory diseases with a wide geographical variability. Risk factors for asthma are both genetic and related to several environmental factors (internal and external pollutants); these also have an important role in the occurrence of COPD. The aim of this study was to describe the prevalence of asthma, COPD, and asthma/COPD overlap (ACO) in an adult population living in two municipalities located in the Po Valley.
METHODS
METHODS
A standardized questionnaire on respiratory symptoms and sociodemographic characteristics was self-administered to a random sample of the adult population aged 20-64 years, living near a refinery in Northern Italy during the period between 2016 and 2019. Logistic and multinomial regression were implemented to explore factors associated with asthma, COPD, and ACO.
RESULTS
RESULTS
In total, 1108 subjects filled out the questionnaire, the mean age was 48.02 ± 12.34 years (range 21-68), and 53% of the respondents/participants were female. Half of the responders were non-smokers, but the frequency of current and former smokers was significantly greater in men than in women (
CONCLUSION
CONCLUSIONS
Respiratory diseases such as asthma and COPD are common in the general population, with differences among countries worldwide. Our findings show, on the basis of the main confirmed risk factor, namely smoking, that it is useful to plan target programs and actions in order to reduce smoking, thus improving the quality of life in public health.
Identifiants
pubmed: 37046964
pii: healthcare11071037
doi: 10.3390/healthcare11071037
pmc: PMC10093894
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Eni (Italy)
ID : Progetto EPI-EST
Références
Lancet Respir Med. 2020 Jun;8(6):585-596
pubmed: 32526187
Immunol Allergy Clin North Am. 2019 May;39(2):163-175
pubmed: 30954168
World Allergy Organ J. 2015 Jul 14;8(1):25
pubmed: 26207160
J Asthma. 2022 Sep;59(9):1908-1913
pubmed: 34469268
Eur Respir J. 2017 Jan 11;49(1):
pubmed: 28077477
Lancet Respir Med. 2017 Sep;5(9):691-706
pubmed: 28822787
Ann Am Thorac Soc. 2014 Jan;11(1):54-62
pubmed: 24251949
Eur Respir J. 1999 Nov;14(5):1044-8
pubmed: 10596688
Allergy. 2019 Dec;74(12):2406-2416
pubmed: 31269237
PLoS One. 2013 May 10;8(5):e62985
pubmed: 23675448
Environ Geochem Health. 2019 Feb;41(1):191-210
pubmed: 30293161
Front Pediatr. 2019 Jun 18;7:246
pubmed: 31275909
J Clin Epidemiol. 2003 Mar;56(3):238-47
pubmed: 12725878
Med Lav. 2010 Sep-Oct;101(5):364-74
pubmed: 21105591
Thorax. 2005 Aug;60(8):645-51
pubmed: 16061705
Eur Respir J. 2022 Feb 15;:
pubmed: 35169025
Eur Respir J. 1995 Aug;8(8):1398-420
pubmed: 7489808
Front Public Health. 2022 Sep 01;10:883784
pubmed: 36117601
Nat Rev Dis Primers. 2015 Dec 03;1:15076
pubmed: 27189863
Lancet Respir Med. 2022 May;10(5):447-458
pubmed: 35279265
PLoS One. 2011 Feb 17;6(2):e16082
pubmed: 21379386
Eur Respir J. 2014 Feb;43(2):374-86
pubmed: 23949964
Can Respir J. 2012 Mar-Apr;19(2):97-102
pubmed: 22536578
PLoS One. 2015 Oct 06;10(10):e0138570
pubmed: 26439263
Eur Respir J. 2019 May 18;53(5):
pubmed: 30846476
Respir Med. 2015 Aug;109(8):1040-7
pubmed: 26052037
Eur Respir J. 1994 May;7(5):954-60
pubmed: 8050554
Int J Chron Obstruct Pulmon Dis. 2018 May 10;13:1507-1514
pubmed: 29785100
PLoS One. 2017 May 18;12(5):e0177538
pubmed: 28542217
Multidiscip Respir Med. 2015 Dec 22;10:39
pubmed: 26697186
Lancet. 2018 Feb 24;391(10122):783-800
pubmed: 29273246
Eur Respir J. 1998 Mar;11(3):599-605
pubmed: 9596109
Int J Environ Res Public Health. 2019 Mar 23;16(6):
pubmed: 30909566
Int Arch Occup Environ Health. 2007 Aug;80(8):711-9
pubmed: 17357796
Environ Health Insights. 2020 Dec 24;14:1178630220985794
pubmed: 33488089
Semin Immunopathol. 2020 Feb;42(1):5-15
pubmed: 32020334
PLoS Med. 2006 Nov;3(11):e442
pubmed: 17132052
Thorax. 2016 Feb;71(2):154-60
pubmed: 26699762
Eur Respir J. 2001 Sep;18(3):598-611
pubmed: 11589359
East Mediterr Health J. 2019 Mar 19;25(1):47-57
pubmed: 30919925
Mater Sociomed. 2012;24(2):100-5
pubmed: 23678316
Int Arch Allergy Immunol. 2010;152(3):255-63
pubmed: 20150743
Nat Energy. 2020 May;5(5):398-408
pubmed: 32483491
BMC Public Health. 2012 Mar 19;12:204
pubmed: 22429515
J Clin Invest. 2019 Apr 1;129(4):1504-1515
pubmed: 30741719
COPD. 2015 Aug;12(4):374-80
pubmed: 25255043
Respir Res. 2019 Oct 23;20(1):229
pubmed: 31647021
Am J Epidemiol. 2007 Apr 15;165(8):927-35
pubmed: 17308332